Cell News and Research

RSS

Class of cells that arises in mammary glands during maternity has stem cell-like properties

These parity-induced mammary epithelial cells (PI-MEC) have the ability to self-renew over many generations and to differentiate into numerous cellular subtypes.

7 Dec 2004

Thalidomide shows promise in fighting myeloma

Thalidomide, a drug often used to treat symptoms of leprosy and in testing to fight HIV, is now demonstrating activity in fighting a common cancer that occurs in bone marrow, myeloma.

6 Dec 2004

New advances in sickle cell disease

Excruciating pain episodes, recurrent pneumonias, strokes, severe infections, chronic hemolytic anemia, and secondary pulmonary hypertension are common complications of sickle cell disease, a life-threatening inherited defect in blood that causes normally disc-shaped red blood cells to take on a sickle shape.

6 Dec 2004

Study on methylisothiazolinone in shampoo lacks a credible scientific basis

Consumers can rest assured that their cosmetic products, including shampoos, are safe. The abstract on Methylisothiazolinone (MI), presented at the Cell Biology 2004 meeting of the American Society for Cell Biology, lacks a credible scientific basis in suggesting that MI could be a safety issue for consumers using personal care products.

6 Dec 2004

Nanogen issued new patent for active biological sample preparation

Nanogen announced today that it was issued U.S. Patent No. 6,824,740, "Apparatus for Active Biological Sample Preparation," by the U.S. Patent and Trademark Office.

6 Dec 2004

Important genetic risk factor for amyotrophic lateral sclerosis

Two Hershey, Pa., researchers were part of a team that has uncovered what may be an important genetic risk factor for amyotrophic lateral sclerosis (ALS).

6 Dec 2004

Scientist develops way to deliver promising genetic tool into living cells

By exploiting an HIV protein that readily traverses cell membranes, Carnegie Mellon University scientists have developed a new way to introduce a gene-like molecule called a peptide nucleic acid (PNA) directly into live mammalian cells, including human embryonic stem (ES) cells.

6 Dec 2004

Common ingredient in some shampoos (methylisothiazolinone) stunts developing neurons of rats

An antimicrobial agent found in some shampoos and hand creams and widely used in industrial settings inhibits the development of particular neuron structures that are essential for transmitting signals between cells.

6 Dec 2004

First live imaging of specialized immune system cells reveals new clues about body’s security system

To keep the body safe, the immune system enlists more than one form of protection. A circulating task force of immune system cells monitors the body’s periphery, and sends information back to field command centers — the lymph nodes — located at pivotal traffic points.

6 Dec 2004

Episome vectors offer fresh angle to gene therapy

A European research team is seeking to overcome the early setbacks suffered by the promising new field of ‘gene therapy’ by developing a revolutionary delivery technique, known as ‘episome vectors’. This breakthrough could pave the way to treating hereditary diseases by injecting the body with healthy versions of damaged genes.

6 Dec 2004

Children with sickle cell disease who are at risk for a stroke need ongoing blood transfusions to reduce their risk

“This important study shows the value of continuing periodic blood transfusions in preventing the serious and debilitating consequences of stroke,” says NHLBI Acting Director Barbara Alving. “At the same time, there are risks of chronic transfusions and the decision to continue with this treatment must be made on a case-by-case basis.”

6 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

Heart Hospital begins experimental cell therapy

Physicians at the Heart Hospital became the first team in the UK to treat a patient with an experimental new therapy designed to repair damage to cardiac muscle resulting from a heart attack. If successful, this treatment would give doctors the ability to improve the hearts of people with heart failure, rather than just treating the symptoms.

6 Dec 2004

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

CHU in Poitiers, France, yesterday announced results of a study showing that newly diagnosed patients with a certain form of leukemia who are treated early with imatinib are more likely to achieve complete cytogenetic responses (the elimination of leukemic cells, a major goal of therapy) and have improved long-term outcomes.

6 Dec 2004

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Genetic target found for pediatric leukemia

A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

Bcl-6 oncogene - genetic target for lymphoma treatment

Results from a pre-clinical study show that the gene designated Bcl-6 is an oncogene -- that is, one with the potential to cause a normal cell to become cancerous -- but that certain peptide inhibitors can in effect inactivate it, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

A new treatment for patients with chronic myeloid leukemia

A new treatment for patients with chronic myeloid leukemia (CML) -- a disorder marked by an overproduction of white blood cells -- yields positive results in those who have relapsed on imatinib, the standard treatment for the disease, according to a Phase I study to be presented today at the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Cell News and Research

Class of cells that arises in mammary glands during maternity has stem cell-like properties

Thalidomide shows promise in fighting myeloma

New advances in sickle cell disease

Study on methylisothiazolinone in shampoo lacks a credible scientific basis

Nanogen issued new patent for active biological sample preparation

Important genetic risk factor for amyotrophic lateral sclerosis

Scientist develops way to deliver promising genetic tool into living cells

Common ingredient in some shampoos (methylisothiazolinone) stunts developing neurons of rats

First live imaging of specialized immune system cells reveals new clues about body’s security system

Episome vectors offer fresh angle to gene therapy

Children with sickle cell disease who are at risk for a stroke need ongoing blood transfusions to reduce their risk

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Heart Hospital begins experimental cell therapy

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Researchers step closer to cure for common childhood cancer

Genetic target found for pediatric leukemia

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Bcl-6 oncogene - genetic target for lymphoma treatment

A new treatment for patients with chronic myeloid leukemia

What are the challenges of cell line development? eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News